Literature DB >> 19868165

FURTHER STUDIES ON THE EPIDEMIOLOGY OF LOBAR PNEUMONIA.

E G Stillman1.   

Abstract

1. Pneumococci of Type I and Type II are responsible for the majority of the cases of lobar pneumonia. 2. Among the pneumococci found in the mouths of healthy individuals Type IV predominates, Type III is frequent, and atypical organisms of Type II are occasionally found. 3. Healthy persons intimately associated with cases of lobar pneumonia may harbor in their mouth secretions the highly parasitic pneumococcus of Types I and II. 4. Occasionally a carrier of Type I or Type II pneumococcus is encountered in whom it is impossible to trace any contact with an infected patient. 5. From the dust of homes where cases of pneumonia due to Types I and II have occurred, pneumococci of the same type may be recovered.

Entities:  

Year:  1917        PMID: 19868165      PMCID: PMC2125790          DOI: 10.1084/jem.26.4.513

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  2 in total

1.  A FURTHER STUDY ON THE BIOLOGIC CLASSIFICATION OF PNEUMOCOCCI.

Authors:  O T Avery
Journal:  J Exp Med       Date:  1915-12-01       Impact factor: 14.307

2.  THE OCCURRENCE OF CARRIERS OF DISEASE-PRODUCING TYPES OF PNEUMOCOCCUS.

Authors:  A R Dochez; O T Avery
Journal:  J Exp Med       Date:  1915-07-01       Impact factor: 14.307

  2 in total
  3 in total

1.  Type I Pneumococcus Otitis Media: (A Case Report and Discussion).

Authors:  J R Paul; C H Wies
Journal:  Yale J Biol Med       Date:  1930-07

2.  The anticipated severity of a "1918-like" influenza pandemic in contemporary populations: the contribution of antibacterial interventions.

Authors:  Yu-Wen Chien; Bruce R Levin; Keith P Klugman
Journal:  PLoS One       Date:  2012-01-23       Impact factor: 3.240

3.  PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES.

Authors:  C M Macleod; R G Hodges; M Heidelberger; W G Bernhard
Journal:  J Exp Med       Date:  1945-11-30       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.